Irritable Bowel Syndrome (IBS) Treatment Global Market Opportunities And Strategies To 2034

Description

Irritable bowel syndrome (IBS) treatment involves a combination of medical, dietary, and lifestyle strategies aimed at managing the chronic gastrointestinal symptoms associated with IBS, such as abdominal pain, bloating, diarrhea, and constipation. The primary purpose of IBS treatment is to reduce symptom severity, improve quality of life, and restore normal bowel function. It may include dietary modifications, stress management, and medications.

The irritable bowel syndrome (IBS) treatment market consists of sales by entities (organizations, sole traders and partnerships) of irritable bowel syndrome (IBS) treatment aim to alleviate symptoms and improve patients' quality of life. IBS treatments are naturally prescribed based on the predominant symptom subtype and are often used in combination with lifestyle modifications, such as diet changes, stress reduction and physical activity.

The global irritable bowel syndrome (IBS) treatment market was valued at $4,575.38 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 8.00%.

Rise In The Prevalence Of Irritable Bowel Syndrome (IBS)

During the historic period, the rise in the prevalence of irritable bowel syndrome (IBS) supported the growth of the irritable bowel syndrome (IBS) treatment market. As IBS is a chronic condition with recurring symptoms like abdominal pain, bloating and altered bowel habits, patients often require long-term and varied treatments. This sustained demand has driven pharmaceutical innovation, increased use of dietary and psychological therapies and expanded diagnostic services. Improved awareness and diagnosis have further widened the treated population, making IBS a significant focus area for healthcare providers and industry players alike. For instance, in 2023, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a US-based non-profit education and research organization, about 5-10% of the global population were affected by Irritable Bowel Syndrome (IBS) in 2023. Additionally, between 25 and 45 million people in the United States are living with IBS. Therefore, the rise in the prevalence of irritable bowel syndrome (IBS) drove the growth of the irritable bowel syndrome (IBS) treatment market.

Focus On Launch Of Microbiome-Based IBS Therapies

Major companies operating in the irritable bowel syndrome (IBS) treatment market are focusing on microbiome-targeted oral therapies such as EBX-102-02, to gain competitive advantage in the market. EBX-102-02 is a next-generation full-spectrum microbiome drug designed to rebalance gut flora and relieve IBS-C symptoms. For example, in March 2025, EnteroBiotix, a US-based clinical-stage biopharmaceutical company, introduced EBX-102-02 in phase 2a trials showing clinically meaningful improvements across multiple symptom domains in IBS-C patients, including IBS-Symptom Severity Scale (IBS-SSS), abdominal pain and stool consistency. This therapy offers target microbiome modulation with oral dosing and favorable tolerability, but outcomes remain preliminary and require larger, longer trials for broader confirmation.

The global irritable bowel syndrome (IBS) treatment market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 38.43% of the total market in 2024.

Irritable Bowel Syndrome (IBS) Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global irritable bowel syndrome (IBS) treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for irritable bowel syndrome (IBS) treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The irritable bowel syndrome (IBS) treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider irritable bowel syndrome (IBS) treatment market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment type, by indication, by distribution channel and by end-users
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment type, by indication, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for irritable bowel syndrome (IBS) treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Treatment Type: Irritable Bowel Syndrome - Constipation-Predominant; Irritable Bowel Syndrome - Diarrhea-Predominant; Probiotic Drugs; Other Treatment Type
2) By indication: IBS With Constipation; IBS With Diarrhea; IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
4) By End-Users: Hospitals; Clinics; Homecare
Companies Mentioned: AbbVie Inc.; Bausch Health; Astellas Pharma AS; Ironwood Pharmaceuticals Inc.; Takeda Pharmaceutical Inc.
Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; irritable bowel syndrome (IBS) treatment indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1783

1 Executive Summary

1.1 Irritable Bowel Syndrome (IBS) Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Irritable Bowel Syndrome (IBS) Treatment Market Definition And Segmentations
6.4 Market Segmentation By Treatment Type
- 6.4.1 Irritable Bowel Syndrome - Constipation-Predominant
- 6.4.2 Irritable Bowel Syndrome - Diarrhea-Predominant
- 6.4.3 Probiotic Drugs
- 6.4.4 Other Treatment Type
6.5 Market Segmentation By Indication
- 6.5.1 IBS With Constipation
- 6.5.2 IBS With Diarrhea
- 6.5.3 IBS With Alternating Constipation And Diarrhea
6.6 Market Segmentation By Distribution Channel
- 6.6.1 Hospital Pharmacies
- 6.6.2 Online Pharmacies
- 6.6.3 Retail Pharmacies
6.7 Market Segmentation By End-Users
- 6.7.1 Hospitals
- 6.7.2 Clinics
- 6.7.3 Homecare Settings

7 Major Market Trends

7.1 Focus On Launch Of Microbiome-Based IBS Therapies
7.2 Increasing Collaborations to Develop Innovative IBS Treatments
7.3 Personalized Nutrition Approaches Accelerate Innovation
7.4 Digital Therapeutics Transform IBS Management

8 Global Irritable Bowel Syndrome (IBS) Treatment Growth Analysis And Strategic Analysis Framework

8.1 Global Irritable Bowel Syndrome (IBS) Treatment PESTEL Analysis
- 8.1.1 Political
- 8.1.2 Economic
- 8.1.3 Social
- 8.1.4 Technological
- 8.1.5 Environmental
- 8.1.6 Legal
8.2 Analysis Of End User (B2B or B2C)
- 8.2.1 Hospitals
- 8.2.2 Clinics
- 8.2.3 Homecare Settings
8.3 Global Irritable Bowel Syndrome (IBS) Treatment Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
- 8.4.1 Market Drivers 2019 - 2024
- 8.4.2 Market Restraints 2019 - 2024
8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
- 8.6.1 Quantitative Growth Contributors
- 8.6.2 Drivers
- 8.6.3 Restraints
8.7 Global Irritable Bowel Syndrome (IBS) Treatment Total Addressable Market (TAM)

9 Global Irritable Bowel Syndrome (IBS) Treatment Market Segmentation

9.1 Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Irritable Bowel Syndrome - Constipation-Predominant, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Irritable Bowel Syndrome - Diarrhea-Predominant, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.7 Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Probiotic Drugs, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.8 Global Irritable Bowel Syndrome (IBS) Treatment Market, Sub-Segmentation Of Other Treatment Type, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Irritable Bowel Syndrome (IBS) Treatment Market, Regional and Country Analysis

10.1 Global Irritable Bowel Syndrome (IBS) Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Irritable Bowel Syndrome (IBS) Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary
11.2 Market Overview
- 11.2.1 Region Information
- 11.2.2 Market Information
- 11.2.3 Background Information
- 11.2.4 Government Initiatives
- 11.2.5 Regulations
- 11.2.6 Regulatory Bodies
- 11.2.7 Major Associations
- 11.2.8 Taxes Levied
- 11.2.9 Corporate Tax Structure
- 11.2.10 Investments
- 11.2.11 Major Companies
11.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
- 11.9.1 Country Information
- 11.9.2 Market Information
- 11.9.3 Background Information
- 11.9.4 Government Initiatives
- 11.9.5 Regulations
- 11.9.6 Regulatory Bodies
- 11.9.7 Major Associations
- 11.9.8 Taxes Levied
- 11.9.9 Corporate Tax Structure
- 11.9.10 Major Companies
11.10 China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
- 11.19.1 Country Information
- 11.19.2 Market Information
- 11.19.3 Background Information
- 11.19.4 Government Initiatives
- 11.19.5 Regulations
- 11.19.6 Regulatory Bodies
- 11.19.7 Major Associations
- 11.19.8 Taxes Levied
- 11.19.9 Corporate Tax Structure
- 11.19.10 Major Companies
11.20 Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.23 South Korea Market
11.24 Summary
11.25 Market Overview
- 11.25.1 Country Information
- 11.25.2 Market Information
- 11.25.3 Background Information
- 11.25.4 Government Initiatives
- 11.25.5 Regulations
- 11.25.6 Regulatory Bodies
- 11.25.7 Major Associations
- 11.25.8 Taxes Levied
- 11.25.9 Corporate Tax Structure
- 11.25.10 Major Companies
11.26 South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.28 South Korea Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Australia Market
11.30 Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.32 Australia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.33 Indonesia Market
11.34 Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.36 Indonesia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate tax structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Irritable Bowel Syndrome (IBS) Treatment Market: Country Analysis
12.7 UK Market
12.8 UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major Companies
13.3 Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Russia Market
13.7 Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.8 Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Irritable Bowel Syndrome (IBS) Treatment Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
- 14.9.1 Country Information
- 14.9.2 Market Information
- 14.9.3 Background Information
- 14.9.4 Government Initiatives
- 14.9.5 Regulations
- 14.9.6 Regulatory Bodies
- 14.9.7 Major Associations
- 14.9.8 Taxes Levied
- 14.9.9 Corporate Tax Structure
- 14.9.10 Investments
- 14.9.11 Major Companies
14.10 USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
- 14.15.1 Country Information
- 14.15.2 Market Information
- 14.15.3 Background Information
- 14.15.4 Government Initiatives
- 14.15.5 Regulations
- 14.15.6 Regulatory Bodies
- 14.15.7 Major Associations
- 14.15.8 Taxes Levied
- 14.15.9 Corporate Tax Structure
- 14.15.10 Investments
- 14.15.11 Major Companies
14.16 Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Major Companies
15.3 South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 Brazil Market
15.7 Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.8 Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Major Companies
16.3 Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Major Companies
17.3 Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Irritable Bowel Syndrome (IBS) Treatment Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

18.1 Company Profiles
18.2 Abbvie Inc.
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Financial Overview
18.3 Bausch Health Companies Inc
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Business Strategy
- 18.3.4 Financial Overview
18.4 Astellas Pharma AS
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Financial Overview
18.5 Ironwood Pharmaceuticals Inc
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Financial Overview
18.6 Takeda Pharmaceutical Company Limited
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 Ardelyx Inc.
- 19.1.1 Company overview
- 19.1.2 Products And Services
19.2 Mallinckrodt Pharmaceuticals plc
- 19.2.1 Company overview
- 19.2.2 Products And Services
19.3 Alfasigma
- 19.3.1 Company overview
- 19.3.2 Products And Services
19.4 Mahana Therapeutics Inc.
- 19.4.1 Company overview
- 19.4.2 Products And Services
19.5 Prometheus Laboratories Inc.
- 19.5.1 Company overview
- 19.5.2 Products And Services
19.6 Cosmo Technologies Ltd.
- 19.6.1 Company overview
- 19.6.2 Products And Services
19.7 Lexicon Pharmaceuticals Inc.
- 19.7.1 Company overview
- 19.7.2 Products And Services
19.8 4D Pharma plc (now known as 4D Pharma)
- 19.8.1 Company overview
- 19.8.2 Products And Services
19.9 OrphoMed
- 19.9.1 Company overview
- 19.9.2 Products And Services
19.10 Boston Pharmaceuticals
- 19.10.1 Company overview
- 19.10.2 Products And Services
19.11 Napo Pharmaceuticals (Acquired by Allergan in 2017)
- 19.11.1 Company overview
- 19.11.2 Products And Services
19.12 Arena Pharmaceuticals
- 19.12.1 Company overview
- 19.12.2 Products And Services
19.13 Tryp Therapeutics
- 19.13.1 Company overview
- 19.13.2 Products And Services
19.14 CinRx Pharma
- 19.14.1 Company overview
- 19.14.2 Products And Services
19.15 Theriva Biologics Inc. (formerly Synthetic Biologics, Inc.)
- 19.15.1 Company overview
- 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 Nerva Acquired Mahana Therapeutics
22.2 Bayer Acquired HiDoc Technologies GmbH
22.3 Roche Acquired Telavant Holdings

23 Recent Developments In Irritable Bowel Syndrome (IBS) Treatment

23.1 Development Of Pediatric Neuromodulation For IBS-Related Pain
23.2 Use Of Targeted Medical Devices

24 Opportunities And Strategies

24.1 Global Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Countries Offering Most New Opportunities
24.2 Global Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Segments Offering Most New Opportunities
24.3 Global Irritable Bowel Syndrome (IBS) Treatment Market In 2029 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 Irritable Bowel Syndrome (IBS) Treatment Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer